Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab ± Apremilast for Moderate-to-Severe Plaque Psoriasis
ChiCTR2600116913Phase 4Not yet recruiting
- Sponsor
- Beijing Luhe Hospital
- Start
- Jan 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in plaque psoriasis comparing Secukinumab monotherapy with Secukinumab + Apremilast combination (2 arms). Primary endpoint: Psoriasis Area and Severity Index (PASI) at week 24. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
secukinumabapremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600116913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116913.